SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series

被引：13
|
作者：
Zampieri, Mattia [1 ,2 ]
Argiro, Alessia [1 ,2 ]
Allinovi, Marco [1 ]
Perfetto, Federico [1 ,3 ]
Cappelli, Francesco [1 ,4 ]
机构：
[1] Careggi Univ Hosp, Tuscan Reg Amyloidosis Ctr, Largo Brambilla 3, I-50134 Florence, Italy
[2] Careggi Univ Hosp, Cardiomyopathy Unit, Florence, Italy
[3] Careggi Univ Hosp, IV Internal Med Div, Florence, Italy
[4] Careggi Univ Hosp, Div Intervent Struct Cardiol, Cardiothoracovasc Dept, Florence, Italy
来源：
INTERNAL AND EMERGENCY MEDICINE | 2022年 / 17卷 / 04期
关键词：
Amyloidosis; SGLT2i; Heart failure; Diabetes; Empaglifozin; Dapagliflozin; Canagliflozin;
D O I：
10.1007/s11739-022-02944-8
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1243 / 1245
页数：3
相关论文
共 50 条
  • [21] Relationship between initial eGFR DIP with proteinuria after SGLT2i treatment, in patients with IgA nephropathy. A real-world clinical study
    Xydakis, Dimitris
    Antonaki, Ergini
    Tzali, Eleni
    Papapanagiotou, Michalis
    Petra, Christina
    Kostakis, Kostantinos
    Vardaki, Eleftheria
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [22] Burden of transthyretin amyloid cardiomyopathy in treatment-naive patients by heart failure severity: results from a large, non-interventional, real-world study
    Cappelli, F.
    Ponti, L.
    Hsu, K.
    Damy, T.
    Villacorta, E.
    Verheyen, N.
    Keohane, D.
    Wang, R.
    Ines, M.
    Kumar, N.
    Munteanu, C.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 : 80 - 81
  • [23] Patient characteristics and drug utilization of heart failure patients prescribed SGLT2i and sacubitril/valsartan, a real-world database cohort study of Optum electronic health record data source
    Loefroth, E.
    Hughes, M.
    Wang, Y.
    Shi, Y.
    Proudfoot, C.
    Di Domenico, M.
    Modgill, V.
    Schlienger, R.
    Studer, R.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 273 - 273
  • [24] IMPACT OF PATISIRAN ON OUTPATIENT HEART FAILURE WORSENING IN PATIENTS WITH CARDIAC TRANSTHYRETIN AMYLOIDOSIS: RESULTS FROM THE APOLLO-B TRIAL
    Fontana, Marianna
    Maurer, Mathew S.
    Gillmore, Julian David
    Bender, Shaun
    Jay, Patrick Y.
    Solomon, Scott D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 511 - 511
  • [25] Identifying Barriers To SGLT2 Inhibitor Use In Eligible Patients With Heart Failure: A Real-world Experience From A Single Centre
    DHALIWAL, A. N. D. Y.
    TOMA, M. U. S. T. A. F. A.
    KOCHAN, A. N. D. R. E. W.
    DIDI, A. H. M. A. D.
    JOURNAL OF CARDIAC FAILURE, 2022, 28 (05) : S48 - S49
  • [26] Efficacy, renal safety and tolerability of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in elderly patients with type 2 diabetes: A real-world experience
    Tumminia, Andrea
    Graziano, Marco
    Vinciguerra, Federica
    Lomonaco, Andrea
    Frittita, Lucia
    PRIMARY CARE DIABETES, 2021, 15 (02) : 283 - 288
  • [27] Mosunetuzumab Monotherapy is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory Follicular Lymphoma who have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study
    Budde, Elizabeth
    Sehn, Laurie H.
    Matasar, Matthew
    Schuster, Stephen J.
    Assouline, Sarit
    Giri, Pratyush
    Kuruvilla, John
    Canales, Miguel
    Dietrich, Sascha
    Fay, Keith
    Ku, Matthew
    Nastoupil, Loretta
    Wei, Michael C.
    Yin, Shen
    Doral, Michelle Y.
    Li, Chi-Chung
    Huang, Huang
    Negricea, Raluca
    Penuel, Elicia
    O'Hear, Carol
    Bartlett, Nancy L.
    El-Sharkawi, Dima
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 18 - 20
  • [28] SGLT2 Inhibitors in Patients with Advanced Heart Failure Awaiting Heart Transplant: Preliminary Results from The SGLT2i-HT Study
    Gallone, G.
    Pidello, S.
    Bertarelli, E.
    Tedeschi, A.
    Maione, D.
    Cacioli, G.
    Pradegan, N.
    Tessari, C.
    Di Nora, C.
    Verde, A.
    Perna, E.
    Raineri, C.
    Marro, M.
    Simonato, E.
    Breviario, F.
    Cavallier, F.
    Amarelli, C.
    Turco, A.
    Vendramin, I.
    Gerosa, G.
    Scelsi, L.
    Della Monica, P. Lilla
    Sinagra, G.
    Garascia, A.
    Merlo, M.
    Rinaldi, M.
    De Ferrari, G. M.
    Boffini, M.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2024, 43 (04): : S516 - S516
  • [29] Real-World Impact of HbA1c Reduction on Treatment Intensification and HbA1c Goal Attainment in T2DM Patients Initiated on SGLT2i
    Brunton, Stephen
    Rozjabek, Heather M.
    Pilon, Dominic
    Lafeuille, Marie-Helene
    Kamstra, Rhiannon L.
    Wynant, Willy
    Bookhart, Brahim
    Lefebvre, Patrick
    DIABETES, 2018, 67
  • [30] Mosunetuzumab Monotherapy is an effective and well-tolerated Treatment Option in Patients with relapsed/refractory follicular Lymphoma who have previously received plus or minus 2 Lines of Therapy: Key Results from a Phase I/II Study
    Hess, G.
    Budde, L. E.
    Sehn, L. H.
    Matasar, M.
    Schuster, S. J.
    Assouline, S.
    Giri, P.
    Kuruvilla, J.
    Canales, M.
    Dietrich, S.
    Fay, K.
    Ku, M.
    Nastoupil, L.
    Wei, M. C.
    Yin, S.
    Doral, M. Y.
    Li, C. -C.
    Huang, H.
    Negricea, R.
    Penuel, E.
    O'Hear, C.
    Bartlett, N. L.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 148 - 148
12345